Skip to main content
. Author manuscript; available in PMC: 2019 Mar 1.
Published in final edited form as: Hepatology. 2018 Jan 30;67(3):1003–1013. doi: 10.1002/hep.29621

Figure 3. Concentration of phenylacetylglutamine (PAGN) in plasma and urine according to renal function.

Figure 3

(A). Plasma PAGN concentration vs. baseline serum creatinine according to maximum infusion rate of OPA. (B). PAGN renal clearance vs. creatinine clearance. (C). Relationship of urinary PAGN clearance to plasma PAGN concentration. Data are shown for patients with “normal” and “impaired renal function” as defined in Methods.

(ORN, ornithine; PA, phenylacetate; PAGN, phenylacetylglutamine).